As part of a series of regular updates on developments in life sciences securities litigation (see Q3 2017 Quarterly Report), this report addresses recent activity in securities actions a...
We previously highlighted the increased activity and some emerging patterns in securities litigation against life sciences companies during the first half of 2017. This report, the first...
Since the CFPB issued its Arbitration Rule in July, most commentators have focused on ways the rule may be blocked from going into effect. Chief among these is the possibility that Congre...
We
previously outlined the growing threat of securities class action lawsuits against life sciences companies and the importance of the United States Supreme Court’s decision in Omnic...
On July 7, 2017, the United States Court of Appeals for the Second Circuit vacated parts of the District Court’s class certification order in In re Petrobras Securities Litigation (“P...
Decision Yesterday and Two Denials of Certiorari Today Decline to Apply American Pipe Tolling to Statutes of Repose Under Both the ’33 Act and ’34 Act
On June 26, 2017, the United St...
The SEC issued two orders concerning violations of Exchange Act Rule 21F-17 this week. On December 19, the Commission issued an order concerning NeuStar Inc., a technology company based ...
To be guilty of insider trading, a tipper of inside information must receive a “personal benefit” in exchange for his tips. On December 6, 2016, the Supreme Court unanimously held in ...
Life sciences companies are frequent targets of securities litigation. Often, when a company discloses bad news about a developing device or drug, the company’s stock price drops and pl...
Today, the Ninth Circuit issued an opinion in SEC v. Jensen. The court held that Rule 13a-14 of the Securities Exchange Act confirms that the SEC has a cause of action against CEOs and C...
